{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"omics_type":["Unknown"],"volume":["7(15)"],"submitter":["Vasseur L"],"pubmed_abstract":["Whether the LSC17 gene expression can improve risk stratification in the context of next generation sequencing-based risk stratification and measurable residual disease (MRD) in patients with intensively treated AML has not been explored. We analyzed LSC17 in 504 adult patients prospectively treated in the ALFA-0702 trial. RUNX1 or TP53 mutations were associated with higher LSC1 scores while CEBPA and NPM1 mutations were associated with lower scores. Patients with high LSC17 scores had a lower rate of complete response (CR) in a multivariable analysis (odds ratio, 0.41; P = .0007), accounting for European LeukemiaNet 2022 (ELN22), age, and white blood cell count (WBC). LSC17-high status was associated with shorter overall survival (OS) (3-year OS: 70.0% vs 52.7% in patients with LSC17-low "],"journal":["Blood advances"],"pagination":["4024-4034"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC10410128"],"repository":["biostudies-literature"],"pubmed_title":["LSC17 score complements genetics and measurable residual disease in acute myeloid leukemia: an ALFA study."],"pmcid":["PMC10410128"],"pubmed_authors":["Lebon D","Dombret H","Heiblig M","Celli-Lebras K","Berthon C","Recher C","Fenwarth L","Duployez N","Lambert J","Dumas PY","Figeac M","Cheok M","Terre C","Itzykson R","Lemasle E","de Botton S","Preudhomme C","Villenet C","Vasseur L"],"additional_accession":[]},"is_claimable":false,"name":"LSC17 score complements genetics and measurable residual disease in acute myeloid leukemia: an ALFA study.","description":"Whether the LSC17 gene expression can improve risk stratification in the context of next generation sequencing-based risk stratification and measurable residual disease (MRD) in patients with intensively treated AML has not been explored. We analyzed LSC17 in 504 adult patients prospectively treated in the ALFA-0702 trial. RUNX1 or TP53 mutations were associated with higher LSC1 scores while CEBPA and NPM1 mutations were associated with lower scores. Patients with high LSC17 scores had a lower rate of complete response (CR) in a multivariable analysis (odds ratio, 0.41; P = .0007), accounting for European LeukemiaNet 2022 (ELN22), age, and white blood cell count (WBC). LSC17-high status was associated with shorter overall survival (OS) (3-year OS: 70.0% vs 52.7% in patients with LSC17-low ","dates":{"release":"2023-01-01T00:00:00Z","publication":"2023 Aug","modification":"2026-05-28T13:05:23.157Z","creation":"2024-12-04T05:25:29.335Z"},"accession":"S-EPMC10410128","cross_references":{"pubmed":["37205853"],"doi":["10.1182/bloodadvances.2023010155"]}}